{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:20Z","timestamp":1792496240287,"version":"4.5.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Obesity is a chronic, recurring, progressive disease and a major public health problem associated with several other diseases that lead to disability, morbidity, and mortality. The prevalence of obesity has increased at pandemic levels, along with increasing weight-related comorbidities and deaths worldwide. Lifestyle interventions alone provide clinically significant long-term weight loss in only a small proportion of individuals, and bariatric surgery is not suitable or desirable for all patients. Historically, anti-obesity medications achieved a mean efficacy with weight loss between 5 and 10%, which significantly impacted several comorbidities and risk factors, but the average efficacy of these medications remained lower than that expected by both patients and health care professionals and eventually curbed long-term use. Moreover, there is no direct evidence on the impact of anti-obesity medications on cardiovascular outcomes. Semaglutide is a newer anti-obesity medication that changes the overall landscape, as phase 3 studies show a mean weight loss near the 15% threshold and significant proportions of patients with a weight loss of greater than 20%. In this review, we focus on the currently available anti-obesity medications, discuss the results of semaglutide, and present perspectives on the future of obesity treatment after semaglutide.<\/jats:p>","DOI":"10.1186\/s13098-023-01233-4","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T06:02:07Z","timestamp":1704261727000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacotherapy for obesity: moving towards efficacy improvement"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-0204","authenticated-orcid":false,"given":"Walmir","family":"Coutinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5065","authenticated-orcid":false,"given":"Bruno","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"1233_CR1","unstructured":"Word Obesity Atlas 2022. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2022. Accessed 5 June 2023."},{"issue":"6","key":"1233_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3810\/pgm.2009.11.2074","volume":"121","author":"X Pi-Sunyer","year":"2009","unstructured":"Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21\u201333.","journal-title":"Postgrad Med"},{"issue":"10","key":"1233_CR3","doi-asserted-by":"publisher","first-page":"e014632","DOI":"10.1136\/bmjopen-2016-014632","volume":"7","author":"A Goettler","year":"2017","unstructured":"Goettler A, Grosse A, Sonntag D. Productivity loss due to overweight and obesity: a systematic review of indirect costs. BMJ Open. 2017;7(10):e014632.","journal-title":"BMJ Open"},{"issue":"7","key":"1233_CR4","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/oby.2004.143","volume":"12","author":"A Peeters","year":"2004","unstructured":"Peeters A, Bonneux L, Nusselder WJ, De Laet C, Barendregt JJ. Adult obesity and the burden of disability throughout life. Obes Res. 2004;12(7):1145\u201351.","journal-title":"Obes Res"},{"issue":"9669","key":"1233_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(09)60318-4","volume":"373","author":"G Whitlock","year":"2009","unstructured":"Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet. 2009;373(9669):1083\u201396.","journal-title":"The Lancet"},{"issue":"10","key":"1233_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006351","volume":"6","author":"A Okunogbe","year":"2021","unstructured":"Okunogbe A, Nugent R, Spencer G, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for eight countries. BMJ Glob Health. 2021;6(10): e006351.","journal-title":"BMJ Glob Health"},{"issue":"8","key":"1233_CR7","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1111\/dom.13752","volume":"21","author":"ID Caterson","year":"2019","unstructured":"Caterson ID, Alfadda AA, Auerbach P, Coutinho W, Cuevas A, Dicker D, et al. Gaps to bridge: misalignment between perception, reality and actions in obesity. Diabetes Obes Metab. 2019;21(8):1914\u201324.","journal-title":"Diabetes Obes Metab"},{"issue":"25 Suppl 2","key":"1233_CR8","first-page":"S102","volume":"129","author":"MD Jensen","year":"2014","unstructured":"Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102\u201338.","journal-title":"Circulation"},{"key":"1233_CR9","unstructured":"ABESO. Diretrizes Brasileiras de Obesidade. https:\/\/abeso.org.br\/wp-content\/uploads\/2019\/12\/Diretrizes-Download-Diretrizes-Brasileiras-de-Obesidade-2016.pdf. Accessed 18 October 2021."},{"issue":"31","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","volume":"192","author":"S Wharton","year":"2020","unstructured":"Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ. 2020;192(31):E875\u201391.","journal-title":"CMAJ"},{"issue":"1","key":"1233_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jand.2015.10.031","volume":"116","author":"HA Raynor","year":"2016","unstructured":"Raynor HA, Champagne CM. Position of the academy of nutrition and dietetics: interventions for the treatment of overweight and obesity in adults. J Acad Nutr Diet. 2016;116(1):129\u201347.","journal-title":"J Acad Nutr Diet"},{"issue":"2","key":"1233_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","volume":"6","author":"DH Ryan","year":"2017","unstructured":"Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6(2):187\u201394.","journal-title":"Curr Obes Rep"},{"issue":"11","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","volume":"4","author":"EW Gregg","year":"2016","unstructured":"Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type-2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913\u201321.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1233_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","volume":"357","author":"L Sj\u00f6str\u00f6m","year":"2007","unstructured":"Sj\u00f6str\u00f6m L, Narbro K, Sj\u00f6str\u00f6m CD, Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741\u201352.","journal-title":"N Engl J Med"},{"issue":"9","key":"1233_CR15","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.2105\/AJPH.2015.302773","volume":"105","author":"A Fildes","year":"2015","unstructured":"Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC. Probability of an obese person attaining normal body weight: cohort study using electronic health records. Am J Public Health. 2015;105(9):e54\u20139.","journal-title":"Am J Public Health"},{"issue":"3","key":"1233_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1037\/0003-066X.62.3.220","volume":"62","author":"T Mann","year":"2007","unstructured":"Mann T, Tomiyama AJ, Westling E, Lew AM, Samuels B, Chatman J. Medicare\u2019s search for effective obesity treatments: diets are not the answer. Am Psychol. 2007;62(3):220\u201333.","journal-title":"Am Psychol"},{"issue":"3","key":"1233_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.amjmed.2008.09.041","volume":"122","author":"H Buchwald","year":"2009","unstructured":"Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type-2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248-56.e5.","journal-title":"Am J Med"},{"issue":"12","key":"1233_CR18","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.2337\/dc12-0193","volume":"35","author":"S Romeo","year":"2012","unstructured":"Romeo S, Maglio C, Burza MA, Pirazzi C, Sj\u00f6holm K, Jacobson P, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;35(12):2613\u20137.","journal-title":"Diabetes Care"},{"issue":"7","key":"1233_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40273-015-0302-y","volume":"33","author":"AS Chawla","year":"2015","unstructured":"Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, et al. Gap between evidence and patient access: policy implications for bariatric and metabolic surgery in the treatment of obesity and its complications. Pharmacoeconomics. 2015;33(7):629\u201341.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1233_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1517\/14740338.2015.995088","volume":"14","author":"B Halpern","year":"2015","unstructured":"Halpern B, Halpern A. Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf. 2015;14(2):185\u20139.","journal-title":"Expert Opin Drug Saf"},{"key":"1233_CR21","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/oby.22810","volume":"28","author":"B Halpern","year":"2020","unstructured":"Halpern B, Mancini C. Should the same safety scrutiny of antiobesity medications be applied to other chronic usage drugs? Obesity. 2020;28:1171.","journal-title":"Obesity"},{"issue":"9","key":"1233_CR22","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/oby.21533","volume":"24","author":"CE Thomas","year":"2016","unstructured":"Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;24(9):1955\u201361.","journal-title":"Obesity (Silver Spring)"},{"key":"1233_CR23","unstructured":"Sharma AM, Birney S, Crotty M, Finer N, Lieberman G, Reynoso RA, et al. Drivers of adherence to medication in obesity management. https:\/\/sciencehub.novonordisk.com\/congresses\/eco2023\/Sharma.html. Accessed 27 June 2023."},{"key":"1233_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23086","author":"LJ Aronne","year":"2021","unstructured":"Aronne LJ. Describing the weight-reduced state: physiology, behavior, and interventions. Obesity (Silver Spring). 2021. https:\/\/doi.org\/10.1002\/oby.23086.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1210\/er.2017-00111","volume":"38","author":"MW Schwartz","year":"2017","unstructured":"Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017;38(4):267\u201396.","journal-title":"Endocr Rev"},{"key":"1233_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.physbeh.2013.07.009","volume":"120","author":"CN Ochner","year":"2013","unstructured":"Ochner CN, Barrios DM, Lee CD, Pi-Sunyer FX. Biological mechanisms that promote weight regain following weight loss in obese humans. Physiol Behav. 2013;120:106\u201313.","journal-title":"Physiol Behav"},{"issue":"5","key":"1233_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41574-018-0148-4","volume":"15","author":"MA van Baak","year":"2019","unstructured":"van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss \u2013 the role of adipose tissue. Nat Rev Endocrinol. 2019;15(5):274\u201387.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"1233_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3945\/ajcn.111.012385","volume":"95","author":"HR Kissileff","year":"2012","unstructured":"Kissileff HR, Thornton JC, Torres MI, Pavlovich K, Mayer LS, Kalari V, et al. Leptin reverses declines in satiation in weight-reduced obese humans. Am J Clin Nutr. 2012;95(2):309\u201317.","journal-title":"Am J Clin Nutr"},{"issue":"17","key":"1233_CR29","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","volume":"365","author":"P Sumithran","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597\u2013604.","journal-title":"N Engl J Med"},{"issue":"12","key":"1233_CR30","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S2213-8587(14)70200-1","volume":"2","author":"K Purcell","year":"2014","unstructured":"Purcell K, Sumithran P, Prendergast LA, Bouniu CJ, Delbridge E, Proietto J. The effect of rate of weight loss on long-term weight management: a randomised controlled trial. Lancet Diabetes Endocrinol. 2014;2(12):954\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1233_CR31","first-page":"2583","volume":"118","author":"M Rosenbaum","year":"2008","unstructured":"Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest. 2008;118(7):2583\u201391.","journal-title":"J Clin Invest"},{"issue":"7","key":"1233_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1467-789X.2009.00654.x","volume":"11","author":"A Schwartz","year":"2010","unstructured":"Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a systematic review. Obes Rev. 2010;11(7):531\u201347.","journal-title":"Obes Rev"},{"issue":"10","key":"1233_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJM199503093321001","volume":"332","author":"RL Leibel","year":"1995","unstructured":"Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332(10):621\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"1233_CR34","first-page":"139","volume":"66","author":"B Halpern","year":"2022","unstructured":"Halpern B, Mancini MC, de Melo ME, Lamounier RN, Moreira RO, Carra MK, et al. Proposal of an obesity classification based on weight history: an official document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). Arch Endocrinol Metab. 2022;66(2):139\u201351.","journal-title":"Arch Endocrinol Metab"},{"issue":"6","key":"1233_CR35","doi-asserted-by":"publisher","first-page":"936","DOI":"10.20945\/2359-3997000000571","volume":"66","author":"B Halpern","year":"2022","unstructured":"Halpern B, Mancini MC, de Melo ME, Lamounier RN, Moreira RO, Carra MK, et al. The new obesity classification based on weight history is not proposed as a guideline. Arch Endocrinol Metab. 2022;66(6):936\u20137.","journal-title":"Arch Endocrinol Metab"},{"key":"1233_CR36","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0005-2760(88)90260-3","volume":"962","author":"B Borgstrom","year":"1988","unstructured":"Borgstrom B. Mode of action of tetrahydrolipstatin, a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta. 1988;962:308\u201316.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"1233_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1432-1033.1991.tb16387.x","volume":"202","author":"S Ransac","year":"1991","unstructured":"Ransac S, Gargouri Y, Moreau H, Verger R. Inactivation of pancreatic and gastric lipases by tetrahydrolipstatin and alkyl-dithio-5-(2-nitrobenzoic acid). A kinetic study with 1,2-didecanoyl-sn-glycerol monolayers. Eur J Biochem. 1991;202(2):395\u2013400.","journal-title":"Eur J Biochem"},{"key":"1233_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s002280050433","volume":"54","author":"LF Van Gaal","year":"1998","unstructured":"Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose ranging study. Eur J Clin Pharmacol. 1998;54:125\u201332.","journal-title":"Eur J Clin Pharmacol"},{"key":"1233_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306\u201313.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"9123","key":"1233_CR40","first-page":"167","volume":"352","author":"L Sj\u00f6str\u00f6m","year":"1998","unstructured":"Sj\u00f6str\u00f6m L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet. 1998;352(9123):167\u201372.","journal-title":"European Multicentre Orlistat Study Group Lancet"},{"issue":"7631","key":"1233_CR41","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194\u20139.","journal-title":"BMJ"},{"issue":"22","key":"1233_CR42","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424\u201334.","journal-title":"JAMA"},{"issue":"1","key":"1233_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155\u201361.","journal-title":"Diabetes Care"},{"issue":"1","key":"1233_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1467-789X.2004.00125.x","volume":"5","author":"S O\u2019Meara","year":"2004","unstructured":"O\u2019Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5(1):51\u201368.","journal-title":"Obes Rev"},{"issue":"4","key":"1233_CR45","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1463-1326.2008.00970.x","volume":"11","author":"S Jacob","year":"2009","unstructured":"Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361\u201371.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1233_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/sj.bjp.0702067","volume":"125","author":"DJ Heal","year":"1998","unstructured":"Heal DJ, Cheetham SC, Prow MR, Martin KF, Buckett WR. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br J Pharmacol. 1998;125(2):301\u20138.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"1233_CR47","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905\u201317.","journal-title":"N Engl J Med"},{"key":"1233_CR48","doi-asserted-by":"crossref","unstructured":"Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study G, et al. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp Clin Endocrinol Diabetes;112: 201\u20137.","DOI":"10.1055\/s-2004-817934"},{"issue":"6","key":"1233_CR49","first-page":"505","volume":"50","author":"IG Smith","year":"2001","unstructured":"Smith IG, Goulder MA. Sibutramine clinical study 1047 team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505\u201312.","journal-title":"J Fam Pract"},{"key":"1233_CR50","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","volume":"160","author":"FG McMahon","year":"2000","unstructured":"McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Arch Int Med. 2000;160:2185\u201391.","journal-title":"Arch Int Med"},{"issue":"9248","key":"1233_CR51","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WP James","year":"2000","unstructured":"James WP, Astrup A, Finer N, Hilsted J, Kopelman P, R\u00f6ssner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. sibutramine trial of obesity reduction and maintenance. Lancet. 2000;356(9248):2119\u201325.","journal-title":"Lancet"},{"key":"1233_CR52","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/sj.ijo.0801592","volume":"25","author":"G Fanghanel","year":"2001","unstructured":"Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. Second phase of a double-blind study clinical trial on sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over. Int J Obes Relat Metab Disord. 2001;25:741\u20137.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1233_CR53","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0002-9343(98)00411-2","volume":"106","author":"M Apfelbaum","year":"1999","unstructured":"Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med. 1999;106:179\u201384.","journal-title":"Am J Med"},{"issue":"5","key":"1233_CR54","first-page":"1","volume":"16","author":"R Ara","year":"2012","unstructured":"Ara R, Blake L, Gray L, Hern\u00e1ndez M, Crowther M, Dunkley A, et al. What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A Syst Rev Health Technol Assess. 2012;16(5):1\u2013195.","journal-title":"A Syst Rev Health Technol Assess"},{"issue":"6","key":"1233_CR55","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01554.x","volume":"14","author":"ID Caterson","year":"2012","unstructured":"Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14(6):523\u201330.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1233_CR56","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/ijo.2015.86","volume":"39","author":"JF Hayes","year":"2015","unstructured":"Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes (Lond). 2015;39(9):1359\u201364.","journal-title":"Int J Obes (Lond)"},{"issue":"10","key":"1233_CR57","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1463-1326.2011.01435.x","volume":"13","author":"EJ Hendricks","year":"2011","unstructured":"Hendricks EJ, Rothman RB. Phentermine therapy for obesity does not elevate blood pressure. Diabetes Obes Metab. 2011;13(10):963\u20134.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1233_CR58","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/oby.22430","volume":"27","author":"KH Lewis","year":"2019","unstructured":"Lewis KH, Fischer H, Ard J, Barton L, Bessesen DH, Daley MF, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4):591\u2013602.","journal-title":"Obesity (Silver Spring)"},{"key":"1233_CR59","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532\u201346.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1233_CR60","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3390\/ph3082398","volume":"3","author":"B Halpern","year":"2010","unstructured":"Halpern B, Oliveira ES, Faria AM, Halpern A, Melo ME, Cercato C, et al. Combinations of drugs in the treatment of obesity. Pharmaceuticals (Basel). 2010;3(8):2398\u2013415.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"1233_CR61","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/obr.12299","volume":"16","author":"HT Hussain","year":"2015","unstructured":"Hussain HT, Parker JL, Sharma AM. Clinical trial success rates of anti-obesity agents: the importance of combination therapies. Obes Rev. 2015;16(9):707\u201311.","journal-title":"Obes Rev"},{"key":"1233_CR62","first-page":"751","volume":"10","author":"C Tek","year":"2016","unstructured":"Tek C. Naltrexone HCI\/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. Patient Prefer Adherence. 2016;10:751\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"1233_CR63","first-page":"A179","volume":"15","author":"P Sinnayah","year":"2007","unstructured":"Sinnayah P, Wallingford N, Evans A, Cowley MA. Bupropion and naltrexone interact synergistically to decrease food intake in mice. Obesity (Silver Spring). 2007;15(9):A179.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"1233_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30\u20139.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"1233_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14740338.2017.1247807","volume":"16","author":"B Halpern","year":"2017","unstructured":"Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release. Expert Opin Drug Saf. 2017;16(1):27\u201339.","journal-title":"Expert Opin Drug Saf"},{"issue":"9741","key":"1233_CR66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595\u2013605.","journal-title":"Lancet"},{"issue":"5","key":"1233_CR67","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935\u201343.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"1233_CR68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110\u201320.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"1233_CR69","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022\u20139.","journal-title":"Diabetes Care"},{"issue":"6","key":"1233_CR70","doi-asserted-by":"publisher","first-page":"e13224","DOI":"10.1111\/obr.13224","volume":"22","author":"AC Sposito","year":"2021","unstructured":"Sposito AC, Bonilha I, Luchiari B, Benchimol A, Hohl A, Moura F, Cercato C, Geloneze B, Nadruz W, Aguilar-Salinas C, Carvalho LSF. Cardiovascular safety of naltrexone and bupropion therapy: systematic review and meta-analyses. Obes Rev. 2021;22(6):e13224.","journal-title":"Obes Rev"},{"issue":"1","key":"1233_CR71","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3","volume":"39","author":"RB Rothman","year":"2001","unstructured":"Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 2001;39(1):32\u201341.","journal-title":"Synapse"},{"issue":"7","key":"1233_CR72","first-page":"423","volume":"6","author":"B Mahgerefteh","year":"2013","unstructured":"Mahgerefteh B, Vigue M, Freestone Z, Silver S, Nguyen Q. New drug therapies for the treatment of overweight and obese patients. Am Health Drug Benefits. 2013;6(7):423\u201330.","journal-title":"Am Health Drug Benefits"},{"issue":"9774","key":"1233_CR73","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341\u201352.","journal-title":"Lancet"},{"issue":"2","key":"1233_CR74","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1233_CR75","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330\u201342.","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"1233_CR76","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.23152","volume":"29","author":"XG Lei","year":"2021","unstructured":"Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and safety of phentermine\/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021;29(6):985\u201394.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"1233_CR77","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/pr.117.014803","volume":"70","author":"TD M\u00fcller","year":"2018","unstructured":"M\u00fcller TD, Clemmensen C, Finan B, DiMarchi RD, Tsch\u00f6p MH. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018;70(4):712\u201346.","journal-title":"Pharmacol Rev"},{"key":"1233_CR78","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","volume":"74","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kushner RF. New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics. Annu Rev Med. 2023;74:125\u201339.","journal-title":"Annu Rev Med"},{"issue":"6","key":"1233_CR79","doi-asserted-by":"publisher","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.","journal-title":"JCI Insight"},{"issue":"2","key":"1233_CR80","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.neuroimage.2006.12.035","volume":"35","author":"N Pannacciulli","year":"2007","unstructured":"Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA, Krakoff J. Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage. 2007;35(2):511\u20137.","journal-title":"Neuroimage"},{"issue":"22","key":"1233_CR81","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"9701","key":"1233_CR82","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606\u201316.","journal-title":"Lancet"},{"issue":"1","key":"1233_CR83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 30 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322.","journal-title":"N Engl J Med"},{"key":"1233_CR84","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial. JAMA. 2015;314:687\u201399.","journal-title":"JAMA"},{"issue":"11","key":"1233_CR85","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/ijo.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443\u201351.","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"1233_CR86","doi-asserted-by":"publisher","first-page":"e12323","DOI":"10.1111\/cob.12323","volume":"9","author":"S Wharton","year":"2019","unstructured":"Wharton S, Kuk JL, Luszczynski M, Kamran E, Christensen RAG. Liraglutide 30 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323.","journal-title":"Clin Obes."},{"key":"1233_CR87","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"J Lundgreen","year":"2021","unstructured":"Lundgreen J, Janus C, Jensen S, Juhl C, Olsen L, Christensen R, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1233_CR88","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3803\/EnM.2020.934","volume":"36","author":"S Moon","year":"2021","unstructured":"Moon S, Lee J, Chung HS, Kim YJ, Yu JM, Yu SH, et al. Efficacy and safety of the new appetite suppressant, liraglutide: a meta-analysis of randomized controlled trials. Endocrinol Metab (Seoul). 2021;36(3):647\u201360.","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"10077","key":"1233_CR89","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399\u2013409.","journal-title":"Lancet"},{"key":"1233_CR90","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1233_CR91","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","volume":"75","author":"SP Marso","year":"2020","unstructured":"Marso SP, Baeres FM, Bain SC, Goldman B, Husain M, Nauck MA, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020;75:1128\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1233_CR92","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10148","key":"1233_CR93","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637\u201349.","journal-title":"Lancet"},{"issue":"9","key":"1233_CR94","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","volume":"41","author":"I Lingvay","year":"2018","unstructured":"Lingvay I, Desouza CV, Lalic KS, Rose L, Hansen T, Zacho J, et al. A 26-week randomized controlled trial of semaglutide once daily versus liraglutide and placebo in patients with type 2 diabetes suboptimally controlled on diet and exercise with or without metformin. Diabetes Care. 2018;41(9):1926\u201337.","journal-title":"Diabetes Care"},{"issue":"11","key":"1233_CR95","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Wilding JPH, Batterham RL, Calanna S, Davies M, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.","journal-title":"N Engl J Med"},{"key":"1233_CR96","doi-asserted-by":"crossref","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","DOI":"10.1016\/S0140-6736(21)00213-0"},{"issue":"14","key":"1233_CR97","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"1233_CR98","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10","key":"1233_CR99","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, J\u00f3dar E, Kandler K, Rigas G, Wadden TA, Wharton S. STEP 5 Study group two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083\u201391.","journal-title":"Nat Med"},{"issue":"2","key":"1233_CR100","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u00b4Neil, PM, Rosenstock, J, S\u00f8rrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022;327(2):138\u201350.","journal-title":"JAMA"},{"issue":"8","key":"1233_CR101","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1233_CR102","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/oby.22359","volume":"27","author":"TA Wadden","year":"2019","unstructured":"Wadden TA, Walsh OA, Berkowitz RI, Chao AM, Alamuddin N, Gruber K, et al. intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring). 2019;27(1):75\u201386.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"1233_CR103","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529\u201336.","journal-title":"Obesity (Silver Spring)"},{"issue":"24","key":"1233_CR104","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M, Gies I, Hesse D, Jeppesen OK, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357.","journal-title":"N Engl J Med"},{"key":"1233_CR105","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23808","author":"AS Kelly","year":"2023","unstructured":"Kelly AS, Arslanian S, Hesse D, Iversen AT, K\u00f6rner A, Schmidt S, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity (Silver Spring). 2023. https:\/\/doi.org\/10.1002\/oby.23808.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"1233_CR106","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/dom.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"1233_CR107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"key":"1233_CR108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. NEJM. 2023. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"NEJM"},{"issue":"9","key":"1233_CR109","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","volume":"29","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358\u201365.","journal-title":"Nat Med"},{"key":"1233_CR110","unstructured":"Research study to investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HfpEF). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04788511. Accessed 5 June 2023."},{"key":"1233_CR111","unstructured":"Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05064735. Accessed 5 June 2023."},{"key":"1233_CR112","unstructured":"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (STEP HfpEF DM). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04916470. Accessed 5 June 2023."},{"issue":"12","key":"1233_CR113","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","volume":"8","author":"K Cl\u00e9ment","year":"2020","unstructured":"Cl\u00e9ment K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960\u201370.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1233_CR114","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S2213-8587(20)30366-1","volume":"8","author":"DH Ryan","year":"2020","unstructured":"Ryan DH. Setmelanotide: what does it mean for clinical care of patients with obesity? Lancet Diabetes Endocrinol. 2020;8(12):933\u20135.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1233_CR115","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.14255","volume":"23","author":"C Gibbons","year":"2021","unstructured":"Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"10286","key":"1233_CR116","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736\u201348.","journal-title":"Lancet"},{"key":"1233_CR117","unstructured":"A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04184622. Accessed 23 September 2021."},{"issue":"3","key":"1233_CR118","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10402","key":"1233_CR119","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613\u201326.","journal-title":"Lancet"},{"issue":"3","key":"1233_CR120","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jama.2017.18519","volume":"319","author":"N Puzziferri","year":"2018","unstructured":"Puzziferri N, Almandoz JP. Sleeve Gastrectomy for weight loss. JAMA. 2018;319(3):316.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"1233_CR121","doi-asserted-by":"publisher","first-page":"e13189","DOI":"10.1111\/obr.13189","volume":"22","author":"AG Dulloo","year":"2021","unstructured":"Dulloo AG. Physiology of weight regain: lessons from the classic minnesota starvation experiment on human body composition regulation. Obes Rev. 2021;22(Suppl 2):e13189.","journal-title":"Obes Rev"},{"issue":"7","key":"1233_CR122","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22493","volume":"27","author":"AP Rossi","year":"2019","unstructured":"Rossi AP, Rubele S, Calugi S, Caliari C, Pedelini F, Soave F, et al. Weight cycling as a risk factor for low muscle mass and strength in a population of males and females with obesity. Obesity (Silver Spring). 2019;27(7):1068\u201375.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"1233_CR123","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1046\/j.1532-5415.2003.51558.x","volume":"51","author":"KE Ensrud","year":"2003","unstructured":"Ensrud KE, Ewing SK, Stone KL, Cauley JA, Bowman PJ, Cummings SR. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc. 2003;51(12):1740\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"1233_CR124","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1210\/jc.2004-1805","volume":"90","author":"KE Ensrud","year":"2005","unstructured":"Ensrud KE, Fullman RL, Barrett-Connor E, Cauley JA, Stefanick ML, Fink HA, et al. Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study. J Clin Endocrinol Metabol. 2005;90(4):1998\u20132004.","journal-title":"J Clin Endocrinol Metabol"},{"issue":"2","key":"1233_CR125","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1080\/07315724.2014.901196","volume":"34","author":"S Agarwal","year":"2015","unstructured":"Agarwal S, Reider C, Brooks JR, Fulgoni VL III. Comparison of prevalence of inadequate nutrient intake based on body weight status of adults in the United States: an analysis of NHANES 2001\u20132008. J Am Col Nutr. 2015;34(2):126\u201334.","journal-title":"J Am Col Nutr"},{"issue":"2","key":"1233_CR126","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3945\/ajcn.2010.29468","volume":"92","author":"CD Gardner","year":"2010","unstructured":"Gardner CD, Kim S, Bersamin A, Dopler-Nelson M, Otten J, Oelrich B, et al. Micronutrient quality of weight-loss diets that focus on macronutrients: results from the A to Z study. Am J Clin Nutr. 2010;92(2):304\u201312.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"1233_CR127","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/oby.23120","volume":"29","author":"A Acosta","year":"2021","unstructured":"Acosta A, Camilleri M, Abu Dayyeh B, Calderon G, Gonzalez D, McRae A, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: a pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021;29(4):662\u201371.","journal-title":"Obesity (Silver Spring)"},{"key":"1233_CR128","doi-asserted-by":"crossref","unstructured":"Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. CMAJ Aug 2020, 192 (31) E875-E891.","DOI":"10.1503\/cmaj.191707"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01233-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T07:08:01Z","timestamp":1704265681000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01233-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":128,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01233-4","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"16 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Walmir Coutinho is a speaker for Novo Nordisk, Brace Pharma and Takeda and an advisory board member of Merck, Novo Nordisk, Abbott Diabetes Care, Takeda and EMS. Bruno Halpern is an advisory board member of Merck, Novo Nordisk, Lilly, and Astra Zeneca and has received funding for lectures from Novo Nordisk, Lilly, Astra Zeneca Boehringer Ingelheim, Takeda, and Abbott Nutrition.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}